Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status

Gynecol Oncol. 1988 Oct;31(2):327-37. doi: 10.1016/s0090-8258(88)80012-x.

Abstract

Forty-six eligible women with metastatic endometrial cancer were randomly allocated to receive monthly cycles of either CAF (cyclophosphamide, adriamycin, 5-fluorouracil) or CAF plus Provera 200 mg daily for 3 weeks followed cyclically by Tamoxifen 20 mg daily for 3 weeks. Overall response rates of 15 and 43% were seen with CAF and CAF plus hormonal therapy. Using a multivariate analysis of the results, this difference is significant (P value 0.05). In 8 patients with operable endometrial cancer, negative estrogen receptor concentration (ER less than 15 fmole/mg protein) and Grade 3 disease, the clinical course was aggressive in 4 patients with systemic and local relapse. In 10 other similar patients (negative ER and Grade 3) who received adjuvant cyclical hormonal therapy only 1 relapsed and the other 9 are disease-free for an average of more than 31 months. Sequential cyclical hormonal therapy with ER and progesterone receptor analysis has a place in the management of endometrial carcinoma.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / analysis
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Medroxyprogesterone / analogs & derivatives*
  • Medroxyprogesterone / therapeutic use
  • Medroxyprogesterone Acetate
  • Middle Aged
  • Multicenter Studies as Topic
  • Neoplasm Recurrence, Local / drug therapy*
  • Prospective Studies
  • Random Allocation
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Remission Induction
  • Tamoxifen / therapeutic use*
  • Uterine Neoplasms / analysis
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / pathology
  • Uterine Neoplasms / radiotherapy

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen
  • Doxorubicin
  • Cyclophosphamide
  • Medroxyprogesterone Acetate
  • Medroxyprogesterone
  • Fluorouracil

Supplementary concepts

  • CAF protocol